All the Drug Class Drugs
HMG-CoA Reductase Inhibitor, Lipid Modifying Agent. Ezetimibe 10 mg, Atorvastatin 10, 20, 40, 80 mg. F.C. TABS.: 30. Hypercholesterolaemia and/or CHD with ACS History). The pt. should be on an appropriate lipid-lower. diet and should cont. on this diet during tmt. with this drug.
The dose range is 10/10 mg/d. through 10/80 mg/d. The typical dose is 10/10 mg ×1/d. The pt’s. low-density lipoprotein cholesterol (LDL-C) level, CHD status, and response to current cholesterol-lower. ther. should be consid. when starting ther. or adjust. the dose.
The dose should be individual. based on the known efficacy of the various dose strengths of and the response to the current cholesterol-lower. ther. Adjust. of dose should be made at intervals of 4 wks. or more.
HoFH: 10/10-10/80 mg dly. The drug may be used as an adjunct to other lipid-lower. tmts. (e.g., LDL apheresis) in these pts. or if such tms. are unavailab.
May be taken with/without food.
Prevent. of Cardiovasc. Event: Indicat. to reduce the risk of cardiovasc. events in pts. with coron. heart dis.(CHD) and a hist. of acute coron. syndr. (ACS), either previous. treated with a statin or not.
Hypercholesterolaemia: The drug indicat. as adjunct. ther. to diet for use in adult. with prim. (heterozygous famil. and non-famil.) hypercholesterolaemia or mixed hyperlipidaemia where use of a comb. product is appropriate, pts. not appropriat. control. with a statin alone, pts. already treated with a statin and ezetimibe.
Homozyg. Familial Hypercholesterolaemia (HoFH): Indicat. as adjunct. ther. to diet for use in adults with HoFH. Pts. may also receive adjunct. tmts. (e.g., low-density lipoprotein [LDL] apheresis).
C/I: Hypersens. Preg., lact. , and in women of child-bear. potent.
HMG-CoA Reductase Inhibitor, Statin. Atorvastatin (as Calcium) 10, 20, 40, 80 mg. Tabs.: 30 X 10, 20 mg, 40 mg, 80mg.
Usual start. dose :10 mg or 20 mg once/day. Dosage range is 10 to 80 mg once/day. Doses should be individualiz. accord. to baseline LDL-C levels, goal of ther., and ptt. resp. Adjust. should be made at intervals of 4 weeks or more. Max. dose is 80 mg once /day.
After init. and/or upon titr., lipid levels should be analyzed within 2 to 4 weeks and dosage adjust. accord. See lit.
Indic. as adjunct to diet for reduct. of elev. total cholesterol, LDL-cholest., apolipoprotein B and triglycerides and to increase HDL Cholesterol in pts. with primary hypercholesterol. includ. familial hypercholesterol. (heterozygous variant) or combined (mixed) hyperlipidemia (correspond. to types IIa and IIb of the fredrickson classification) when resp. to diet and other non-pharmacol. measures is inadeq.
Also indic. to reduce total-C and LDL-C in pts. with homozygous familial hypercholesterol. as an adjunct to other lipid-lowering tmt. (e.g. LDL apheresis) or if such tmts. are unavailable.
Ped. pts. (10-17 years of age):
indic. as adjunct to diet to reduce total-C, LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age, with heterozygous familial hypercholesterol. if after an adeq. trial of diet ther. the follow. findings are present:
1. LDL-C remains >or = 190 mg/dl or
2. LDL-C remains >or = 160 mg/dl and: there is a posit. family hist. of premature cardiovasc. dis. or two or more other CVD risk factors in the ped. ptt.
Prevent. of CV and/or cerebrovasc. event such as MI or stroke as adjunct to correct. of other risk factors such as hypertens. in pt.s with three or more addit. risk factors or diabetes with one addit. risk factor.
In pts. with clin. evident coron. heart disease, indic. to:
Red. risk of non-fatal MI.
Red. risk of fatal and non-fatal stroke.
Red. the risk for revascular. procedures.
Red. the risk of hospitaliz. for CHF.
Red. the risk of angina.
C/I:
Ac. liver fail. or decompens. cirrhosis.
Hypersens. to atorvastatin or to excipts. Hypersens. reactions, incl. anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndr. and toxic epiderm. necrol. have been reported.
See lit.
